SCHEMBL25328014

SCHEMBL25328014

CSc1ncc2c(F)cc(B(O)O)n2n1

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25326864 0.77
SCHEMBL25327119 0.71 KDM4E (0.32) KDM4E
SCHEMBL25328839 0.70 AURKA (0.30)
SCHEMBL25325595 0.70 LMNA (0.39) KDM4E
SCHEMBL25328050 0.65
SCHEMBL519840 0.64 KDM4E (0.31) KDM4E
SCHEMBL19222025 0.63 CKS1B (0.31) KDM4E
SCHEMBL482203 0.60 MEN1 (0.36) KDM4E
SCHEMBL25327280 0.58 NR1I2 (0.33) KDM4E
SCHEMBL519842 0.58 KDM4E (0.38) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163063-A1 INHIBITORS OF CDK4/6 KINASE KHORA SPV 1, LLC 2025-05-22 US disclosed
EP-4469062-A1 INHIBITORS OF CDK4/6 KINASE Kinnate Biopharma Inc. (US) 2024-12-04 EP disclosed
CN-119013030-A Inhibitors of CDK4/6 kinase 金耐特生物制药公司 2024-11-22 CN disclosed
WO-2023147372-A1 INHIBITORS OF CDK4/6 KINASE KINNATE BIOPHARMA INC. (US) 2023-08-03 WO disclosed
WO-2023147372-A1 INHIBITORS OF CDK4/6 KINASE KINNATE BIOPHARMA INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163063-A1 INHIBITORS OF CDK4/6 KINASE CDK4, CDK6, CDK2 KDM4E 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.